List of Cell Therapies Companies in United Kingdom - 39

4basebio is enabling next generation cell and gene therapies and vaccines with its technologies and solutions. We are able to design, manufacture and supply application-specific synthetic DNA or mRNA as well as targeted non-viral vectors for the delivery of nucleic acid payloads. Our novel synthetic DNA technology offers unique customisation potential, rapid turn-around times, and improved safety profiles, addressing the current limitations of plasmids and other DNA technologies. We currently offer four DNA construct types, each ideally suited for use in viral and non-viral vector applications, genome editing, vaccines and therapeutics, and DNA vaccine applications, respectively. Our proprietary non-viral delivery system, Hermes™, is a nanoparticle vector that can be customised to target cells or tissues of interest for a range of applications. This combines the safety and efficiency of lipid-based nanoparticles (LNPs) with the specificity of a targeting system, addressing the shortcoming associated with both viral vectors and non-targeted LNPs.

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company’s lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Driven by innovative science and our entrepreneurial culture, we are focused on the delivery of life-changing medicines that are fuelling growth and contributing value to patients and society.

Since 1987, Astrea Bioseparations has been pioneering the design, development and manufacture of affinity purification technology for lab-scale and industrial-scale bioprocessing. With over 25 years experience and success in the development of affinity products and design of new custom adsorbents, Astrea is a world leader in its field. Astrea Bioseparations has sales and support offices in North America and Europe, R&D facilities in Cambridge, UK and manufacturing facilities located on the Isle of Man, British Isles and Joliette, QC, Canada ensuring that we are able to meet your needs and support your application wherever you are. OUR EXPERTISE: • Extensive range of bioseparation products • Custom designed chromatography adsorbents • Over 25 years experience & success • Cost effective solutions • Proven Mimetic Ligand™ technology • Dedicated professional service • Full technical support & in-house training • Experts in adsorbent development & downstream process optimization • Established manufacturing facility (ISO 9001)

Focused on the development of precisely targeted, controlled and highly active T cell therapies that are designed to offer cancer patients substantial benefits over existing standard of care.

At AviadoBio, we are relentlessly chasing cures by translating groundbreaking science and precision delivery into life-changing medicines for people living with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). With our deep understanding of the brain and our suite of proprietary gene therapy platforms and delivery technologies, we are working relentlessly to overcome the challenges of delivering the right drug to the right place. Our innovative, neuroanatomy-led approach is designed to maximize the therapeutic potential of gene therapy to halt or potentially reverse neurodegenerative diseases. The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.

Axovia Therapeutics is dedicated to the research and development of novel AAV gene therapies that target key aspects of ciliopathies, addressing the devastating impact of the disease head-on for patients, their families and caregivers. Axovia is currently developing therapies for patients with mutations in the BBS1 gene which manifests as Bardet Biedl Syndrome. Our initial goal is to halt the progression of BBS by targeting the most debilitating aspects of the neurological, metabolic and retinal dysfunctions.

Bastion Therapeutics is a preclinical stage biotechnology company with a mission to develop novel Treg therapies to address the unmet clinical need for inflammatory disorders. We leverage our proprietary GRIT™ platform technology to enhance Tregs to modulate the immune system and overcome challenges associated with previous generations of Treg therapies. Our vision is to provide life-changing therapies that are efficacious, durable and safe to patients suffering from inflammatory disorders.

Biosceptre is developing a multi-targeted universal CAR-T system, designed to incorporate our nfP2X7 technology, to be capable of treating a range of cancers.

Broken String Bioscience’s technology platform, INDUCE-seq™, supports the development of cell and gene therapies that are safer by design. INDUCE-seq™, is an NGS-based DNA break mapping platform that enables companies developing cell and gene therapies to measure and quantify the specificity of off-target genetic edits and evaluate the associated genetic outcomes. The platform provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages to advance gene editing programs

For over 30 years, FUJIFILM Diosynth Biotechnology’s mission has been advancing tomorrow’s medicine. As a CDMO, we work in partnership with the most innovative biopharma and biotech companies across the world who are reimagining healthcare’s potential. We help to accelerate their progress, expand their capabilities, streamline their processes, and strengthen their innovation. So when our customers’ potential cures, vaccines, biologics, and accomplishments make strides – or even become new realities for patients – we know our work, our manufacturing expertise, and our partnership helped make it happen. FDB isn’t simply a workplace. It’s a place of passion – a place of what we call Genki. A place where diverse perspectives and people come to life. Where opportunity for growth has no end. Where passion is followed, discovered, and nurtured. Where the energy is undeniable, enthusiasm is pervasive, and drive is infectious. All of our global locations burst with curiosity, inspiration, and extraordinary purpose. So as we continue to grow our teams, our global locations, and our capabilities, Genki will always be our cultural tie. That’s why we’re always looking for passionate, mission-driven people who want to commit their life’s work to enabling better outcomes for patients and their families. For a full listing of jobs that will propel, inspire, and fulfill you, please visit: fujifilmdiosynth.com/careers/ We created this space on LinkedIn to give people a window into work and culture at FDB. We’re highlighting employees’ passion, current openings, and why it’s never been a more exciting time to join FDB.

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Discovering and developing innovative medicines to preserve people’s sight and fight the devastating impact of blindness around the world.

Intima Bioscience - A clinical stage gene and cell therapy company focused on curative intent in solid tumor cancer

Laverock was founded around the core Gene Editing induced Gene Silencing Platform – a step-change in RNAi technology. We fundamentally believe it unlocks the development of next-generation therapeutics through its unique and differentiated properties. We are actively developing a pipeline of GEiGS enabled ex vivo cell therapies, as well in vivo therapeutic approaches.

Leucid is progressing novel CAR T therapies that produce a better and more durable response than previous CAR T generations, improving treatment outcomes and saving the lives of patients with refractory cancers.

LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering (e.g. CARs). The resulting CAR-IMAN cells give cancer patients potentially hundreds of times the cancer killing ability they naturally possess.

Malvern Panalytical is a global leader in the analytics of material and life sciences. We unleash the power of small things to make big things happen for our customers. Our vision is to make the world cleaner, healthier, and more productive. We partner with our customers to make their solutions possible through the power of precision measurements, our expertise, trusted data, and insights. Our people are partners in discovery. We collaborate with our customers and with each other to discover new possibilities and achieve breakthroughs. Our culture is a healthy, high-performance culture shaped by our values: Own it, Aim High and Be True. We’re committed to Net Zero in our own operations by 2030 and in our total value chain by 2040. With over 2300 employees across the globe, we are part of Spectris plc, the world-leading precision measurement group. Malvern Panalytical. We’re BIG on small™

Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems, 2020). The platforms, MOGRIFY® and epiMOGRIFY®, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type. Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease. Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development partnerships, as well as the exploitation of the platform in other therapeutic and non-therapeutic applications. Based in Cambridge, UK, the Company has raised over $40 million USD funding from Parkwalk, Ahren Innovation Capital, 24Haymarket, Trend Investment Group, Dr. Darrin M. Disley, OBE, Dr. Jonathan Milner and the University of Bristol Enterprise Fund III, as well as strategic investors; Astellas Venture Management.

NK:IO reimagines cancer treatment. By harnessing the potential of the innate immune system, we are developing ground breaking NK cell and small molecule therapies targeting both haematological and solid tumours. Our technologies are built on pioneering research carried out by Hugh Brady and Matthew Fuchter at Imperial College, London. Based on their discoveries we have developed three interrelated, proprietary technology platforms.

Orchard Therapeutics, a Kyowa Kirin company, is a global gene therapy leader focused on ending the devastation caused by genetic and other severe diseases by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease with a single treatment. Founded in 2015, Orchard’s roots go back to some of the first research and clinical developments involving HSC gene therapy. Our team has played a central role in the evolution of this technology from a promising scientific idea to a potentially life-transforming reality. Today, Orchard is advancing a pipeline of HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist. For more information, please visit www.orchard-tx.com.

Ori Biotech is a London- and Philadelphia-based leader in CGT manufacturing technology that has developed a proprietary, bespoke and flexible manufacturing platform, which enables patient access to a new generation of personalized, lifesaving treatments. By fully automating and standardizing CGT manufacturing in a closed platform, Ori offers therapeutics developers the opportunity to seamlessly scale from pre-clinical process development to commercial scale manufacturing. So complex manufacturing challenges can be put where they belong – in the past.

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

Plasticell is a biotechnology company that develops novel therapies through precise manipulation of stem cells and more differentiated cell types using award-winning combinatorial screening technology. Technolgy Innovate cell-based combinatorial screening technology allows us to develop optimised protocols for cell expansion, cell differentiation, gene transduction, biomolecule production as well as the provision of human cells for use in drug discovery. Pipeline Out therapeutic projects include advanced cell and gene therapies as well as drugs discovered by screening rare human cell types derived from stem cells Visit our website www.plasticell.co.uk for more details.

Prokarium is pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects.

An exciting new cell therapy immunology biotech committed to transforming patient's lives in solid organ transplantation and auto-immune conditions. Our company is growing and we are exciting about the future! Our vision is to become a world leader in new cell therapy and the people are at the heart of what we do. We treat our people with respect, working collaboratively across the business, taking ownership and accountability for the outcomes and results we delivery. Most of all we work with integrity to innovate and bring the best version of ourselves to the job every day.

Our focus at ReNeuron is on our CustomEx exosome technology platform, producing exosomes with unique tissue targeting tropisms to deliver a payload of choice to a preferred cell type. Our mission is to partner and develop novel exosome therapeutics for diseases with significant unmet needs.

Rinri Therapeutics is a private biotechnology company developing first-in-class cell therapies to restore hearing. Hearing loss affects 350m people in the world; 90% caused by sensorineural hearing loss (SNHL). There are currently no disease-modifying therapeutics for SNHL patients. Rinri's pioneering technology seeks to reverse SNHL through the regeneration of the damaged sensory cells in the inner ear, the cochlea. Rinri is backed by Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures, BioCity and the University of Sheffield.

Develop safe and effective drug delivery systems for cell andgene therapeutics.

TC BioPharm is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. We have a growing team based in our Glasgow office, alongside a wide range of scientific advisors, and partner organisations.

T-Cypher Bio is an early-stage, innovative biotechnology company based in Oxford, UK. We believe that TCR-based therapeutics have the potential to transform the treatment of solid tumours, as well as autoimmune & inflammatory conditions. Yet challenges in the identification of therapeutically relevant targets and TCRs has limited the application of such therapies. Our goals: - Develop next generation TCR therapies for treatment of cancer and autoimmune disease - Innovate to make TCR therapies widely available to patients About T-Cypher - Founded in 2021 based on exclusive technology licenses from University of Oxford, and with Oxford Science Enterprises as the major shareholder - Proprietary disease target and TCR discovery platform - Expanding TCR-bank against novel, differentiated targets - Differentiated approach to multiplexing TCRs in therapeutic T-cells - Diverse team with experienced leadership from prominent companies covering cell therapy, gene engineering, immune oncology, autoimmune disease and computational biology

Tenpoint Therapeutics Limited is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts and geographic atrophy. Its lead asset, BRIMOCHOL PF, is a novel, pupil-modulating therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that afflicts approximately 2 billion people globally. BRIMOCHOL PF has completed its first Phase 3 pivotal trial (BRIO-I) and will complete the second pivotal study, BRIO-II, in 2025. This topical ophthalmic is poised for launch in 2026. Tenpoint’s leadership team includes ophthalmic industry luminaries with track records of successful approvals and commercialization of blockbuster drugs. A privately held company, Tenpoint Therapeutics is backed by AdBio Partners, British Patient Capital, Eight Roads, EQT Life Sciences, F-Prime Capital, Hillhouse Capital Management, Qiming Venture Partners USA, Sofinnova Partners, and UCL Technology Fund.

TrakCel design, deploy and support digital Cellular Orchestration Solutions that track and manage all the components of the Cell and Gene Therapy supply chain, helping therapy developers to deliver therapies to patients safely and efficiently for both clinical and commercial stage therapies. For each Advance Therapy Patient journey, from sample collection through logistics, manufacturing and final treatment, TrakCel's flagship platform, OCELLOS orchestrates every step, providing a comprehensive chain of custody, chain of identity and traceability throughout. Always remembering there is a patient at the end of everything we do. We innovate. We unite. We transform tomorrow. Want to know more about how TrakCel could transform your therapy supply chain, get in touch and book a free product demo. Join us. See the journey.

T-Therapeutics is a next-generation TCR company, spun out from the University of Cambridge, deeply rooted in world-leading academic science. We are developing ‘optimal’ TCR based therapeutics using our proprietary OpTiMus® platform, based on a fully humanized TCR mouse that provides an almost unlimited source of unique, antigen-specific human TCRs. We combine world-leading expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration.